e-Drug3D
1575
LORCASERIN
INN
LORCASERIN
cas 616202-92-7
CLASS
METABOLISM
SEROTONIN 2C RECEPTOR AGONIST 5-HT2C (KD = 13 NANOMOLAR)
5-HT2B (KD = 147 NANOMOLAR)
5-HT2A (KD = 92 NANOMOLAR)
WEIGHT MANAGEMENT IN ADULTS
ANOREXIGENIC
ROUTE (list)
ORAL
ATC code
A08AA11
PK parameters
Tmax 1.75 HOUR
PPB 70 PERCENT
t1/2 11 HOUR
Solubility
SOLUBILITY IN WATER GREATER THAN 400 MILLIGRAM / MILLILITER
TARGET SEROTONIN 2C RECEPTOR (5-HT2C)
5-hydroxytryptamine receptor 2C UNIPROT P28335 HTR2C
Formula:
C11H14ClN
Calculated chemical properties:
MW 195.68
NB_atoms 13
XLogP 2.59
PSA 14.269
NB_HD 1
NB_HA 1
fsp3 0.45
Lipinski(0=no;1=yes) 1
NB_atoms 13
XLogP 2.59
PSA 14.269
NB_HD 1
NB_HA 1
fsp3 0.45
Lipinski(0=no;1=yes) 1
FDA
NDA 022529 (label) INN (LORCASERIN HYDROCHLORIDE) BELVIQ (EISAI INC) APPROVAL= AP YEAR= 2012 NEWMOLECULARENTITY DISCONTINUED OBSOLETE
NDA 208524 (label) INN (LORCASERIN HYDROCHLORIDE) BELVIQ XR (EISAI INC) APPROVAL= AP YEAR= 2016 DISCONTINUED OBSOLETE
NDA 209464 (pdf not found) INN (LORCASERIN HYDROCHLORIDE) LORCASERIN HYDROCHLORIDE (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2019
NDA 022529 (label) INN (LORCASERIN HYDROCHLORIDE) BELVIQ (EISAI INC) APPROVAL= AP YEAR= 2012 NEWMOLECULARENTITY DISCONTINUED OBSOLETE
NDA 208524 (label) INN (LORCASERIN HYDROCHLORIDE) BELVIQ XR (EISAI INC) APPROVAL= AP YEAR= 2016 DISCONTINUED OBSOLETE
NDA 209464 (pdf not found) INN (LORCASERIN HYDROCHLORIDE) LORCASERIN HYDROCHLORIDE (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2019